BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 27232516)

  • 1. Recent advances in immunotherapy for kidney cancer.
    Ball MW; Allaf ME; Drake CG
    Discov Med; 2016 Apr; 21(116):305-13. PubMed ID: 27232516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging role for novel immunotherapy agents in metastatic renal cell carcinoma: from bench to bedside.
    Weinstock M; McDermott DF
    Am Soc Clin Oncol Educ Book; 2015; ():e291-7. PubMed ID: 25993188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging immunotherapy in advanced renal cell carcinoma.
    Mendiratta P; Rini BI; Ornstein MC
    Urol Oncol; 2017 Dec; 35(12):687-693. PubMed ID: 28889919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy for kidney cancer: status quo and the future.
    Bedke J; Stühler V; Stenzl A; Brehmer B
    Curr Opin Urol; 2018 Jan; 28(1):8-14. PubMed ID: 29120911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immunotherapeutic strategies in development for renal cell carcinoma.
    Inman BA; Harrison MR; George DJ
    Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
    Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
    Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical decision-making for immunotherapy in metastatic renal cell carcinoma.
    Schmidinger M
    Curr Opin Urol; 2018 Jan; 28(1):29-34. PubMed ID: 29045250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma: recent progress and future directions.
    Mulders P; Figlin R; deKernion JB; Wiltrout R; Linehan M; Parkinson D; deWolf W; Belldegrun A
    Cancer Res; 1997 Nov; 57(22):5189-95. PubMed ID: 9371523
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel immunotherapy in metastatic renal cell carcinoma.
    Cho YH; Kim MS; Chung HS; Hwang EC
    Investig Clin Urol; 2017 Jul; 58(4):220-227. PubMed ID: 28681030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
    Massari F; Santoni M; Ciccarese C; Santini D; Alfieri S; Martignoni G; Brunelli M; Piva F; Berardi R; Montironi R; Porta C; Cascinu S; Tortora G
    Cancer Treat Rev; 2015 Feb; 41(2):114-21. PubMed ID: 25586601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TroVax in colorectal cancer.
    Rowe J; Cen P
    Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
    Biswas S; Eisen T
    Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of immunotherapy in kidney cancer.
    Nazzani S; Bazinet A; Karakiewicz PI
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):325-333. PubMed ID: 30048250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'nivolution' in renal cell carcinoma: behind the scenes of clinical trials.
    Buti S; Bersanelli M
    Future Oncol; 2016 Sep; 12(18):2061-3. PubMed ID: 27168416
    [No Abstract]   [Full Text] [Related]  

  • 16. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of nivolumab for the treatment of metastatic renal cell carcinoma.
    Zarrabi K; Wu S
    Expert Opin Biol Ther; 2018 Jun; 18(6):695-705. PubMed ID: 29782188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging immunotherapies for renal cell carcinoma.
    Escudier B
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii35-40. PubMed ID: 22918926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy in renal cell carcinoma.
    Gul A; Rini BI
    Cancer; 2019 Sep; 125(17):2935-2944. PubMed ID: 31225907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunomodulatory Therapies for Renal Cell Carcinoma.
    Liu M; Wu H; Shangguan D; Jiang Y; Li X; Liu S; Zhou B; Yin T; Gong Z
    Protein Pept Lett; 2018; 25(6):534-547. PubMed ID: 29848257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.